AU783282C - Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof - Google Patents

Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof

Info

Publication number
AU783282C
AU783282C AU39702/01A AU3970201A AU783282C AU 783282 C AU783282 C AU 783282C AU 39702/01 A AU39702/01 A AU 39702/01A AU 3970201 A AU3970201 A AU 3970201A AU 783282 C AU783282 C AU 783282C
Authority
AU
Australia
Prior art keywords
individual
antibody
treatment
conjugate
affinity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU39702/01A
Other languages
English (en)
Other versions
AU3970201A (en
AU783282B2 (en
Inventor
Matthew D Linnik
Patricia A. Mcneeley
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
La Jolla Pharmaceutical Co
Original Assignee
La Jolla Pharmaceutical Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by La Jolla Pharmaceutical Co filed Critical La Jolla Pharmaceutical Co
Publication of AU3970201A publication Critical patent/AU3970201A/en
Publication of AU783282B2 publication Critical patent/AU783282B2/en
Application granted granted Critical
Publication of AU783282C publication Critical patent/AU783282C/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU39702/01A 1999-11-28 2000-11-28 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof Ceased AU783282C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US16771699P 1999-11-28 1999-11-28
US60/167716 1999-11-28
PCT/US2000/042307 WO2001041813A2 (en) 1999-11-28 2000-11-28 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof

Publications (3)

Publication Number Publication Date
AU3970201A AU3970201A (en) 2001-06-18
AU783282B2 AU783282B2 (en) 2005-10-06
AU783282C true AU783282C (en) 2006-04-06

Family

ID=22608518

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39702/01A Ceased AU783282C (en) 1999-11-28 2000-11-28 Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof

Country Status (11)

Country Link
US (2) US7081242B1 (https=)
EP (1) EP1233791A2 (https=)
JP (1) JP2003516526A (https=)
KR (1) KR20020059808A (https=)
CN (2) CN101422614A (https=)
AU (1) AU783282C (https=)
CA (1) CA2391944A1 (https=)
HK (1) HK1045944A1 (https=)
MX (1) MXPA02005236A (https=)
NO (1) NO20022441L (https=)
WO (1) WO2001041813A2 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
MXPA02005236A (es) 1999-11-28 2004-03-19 Jolla Pharma Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
US20030114405A1 (en) * 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
WO2004060320A2 (en) * 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20040258683A1 (en) * 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals
US20060229270A1 (en) * 2005-03-10 2006-10-12 La Jolla Pharmaceutical Company Methods of treating proteinuria by reducing double-stranded DNA antibodies
WO2009052415A1 (en) * 2007-10-17 2009-04-23 The Regents Of The University Of California Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus
CN102477079A (zh) * 2010-11-24 2012-05-30 中国人民解放军军事医学科学院基础医学研究所 一种新型多肽在系统性红斑狼疮诊断中的应用
WO2012116210A2 (en) * 2011-02-23 2012-08-30 The Regents Of The University Of California Peptide for the induction of immune tolerance as treatment for systemic lupus erythematosus

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6022544A (en) 1983-01-24 2000-02-08 The John Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5126131A (en) 1983-01-24 1992-06-30 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of antigen-competitive conjugates.
US5370871A (en) 1983-01-24 1994-12-06 The Johns Hopkins University Therapeutic suppression of specific immune responses by administration of oligomeric forms of antigen of controlled chemistry
US5162515A (en) 1990-01-16 1992-11-10 La Jolla Pharmaceutical Company Conjugates of biologically stable polymers and polynucleotides for treating systemic lupus erythematosus
US5268454A (en) 1991-02-08 1993-12-07 La Jolla Pharmaceutical Company Composition for inducing humoral anergy to an immunogen comprising a t cell epitope-deficient analog of the immunogen conjugated to a nonimmunogenic carrier
US5552391A (en) 1990-01-16 1996-09-03 La Jolla Pharmaceutical Company Chemically-defined non-polymeric valency platform molecules and conjugates thereof
US5391785A (en) 1990-01-16 1995-02-21 La Jolla Pharmaceutial Company Intermediates for providing functional groups on the 5' end of oligonucleotides
AU8869291A (en) 1990-10-04 1992-04-28 University Of Virginia Alumni Patents Foundation, The Primate erythrocyte bound monoclonal antibody heteropolymers
JP2899111B2 (ja) 1991-07-15 1999-06-02 ラ ホヤ ファーマシューティカル カンパニー オリゴヌクレオチドの５’末端へ官能基を提供するための修飾された亜リン酸中間体
KR100361933B1 (ko) 1993-09-08 2003-02-14 라 졸라 파마슈티칼 컴파니 화학적으로정의된비중합성결합가플랫폼분자및그것의콘주게이트
ES2282988T3 (es) * 1993-09-08 2007-10-16 La Jolla Pharmaceutical Company Moleculas plataforma de valencia no polimericas,.
AU696964B2 (en) 1994-02-28 1998-09-24 University Of Virginia Patent Foundation Antigen-based heteropolymers and method for treating autoimmune diseases using the same
US5874409A (en) 1995-06-07 1999-02-23 La Jolla Pharmaceutical Company APL immunoreactive peptides, conjugates thereof and methods of treatment for APL antibody-mediated pathologies
US5856464A (en) 1995-06-07 1999-01-05 Lajolla Pharmaceutical Company Selective capping solution phase oligonucleotide synthesis
KR20000016414A (ko) 1996-06-06 2000-03-25 와이즈먼 앤드루 Apl 면역반응성 펩티드, 그것의 콘주게이트 및 apl항체-매개병변의 치료방법
US5817752A (en) 1996-06-06 1998-10-06 La Jolla Pharmaceutical Company Cyclic polypeptides comprising a thioether linkage and methods for their preparation
DE69825576T2 (de) 1997-04-11 2005-08-11 Chiyoda Corp., Yokohama Katalysator für die herstellung von synthesegas und verfahren zur herstellung von kohlenmonoxid
US7794946B1 (en) 1998-02-04 2010-09-14 Life Technologies Corporation Microarray and uses therefor
JP4078032B2 (ja) 1998-03-12 2008-04-23 ネクター セラピューティックス エイエル，コーポレイション 近位の反応性基を持つポリ（エチレングリコール）誘導体
US6858210B1 (en) 1998-06-09 2005-02-22 La Jolla Pharmaceutical Co. Therapeutic and diagnostic domain 1 β2GPI polypeptides and methods of using same
MXPA01002580A (es) 1998-09-10 2002-04-08 Univ Virginia Anticuerpos para c3b(1) para el suministro de agentes de diagnostico y terapeuticos para celulas cancerosas.
US6572856B1 (en) 1998-09-10 2003-06-03 The University Of Virginia Patent Foundation Methods for the prevention and treatment of cancer using anti-C3b(i) antibodies
JP2002531531A (ja) 1998-12-09 2002-09-24 ラ ホヤ ファーマシューティカル カンパニー 循環している抗体を減少させるための方法および処方物
US6399578B1 (en) 1998-12-09 2002-06-04 La Jolla Pharmaceutical Company Conjugates comprising galactose α1,3 galactosyl epitopes and methods of using same
US20010010818A1 (en) 1998-12-09 2001-08-02 Engle Steven B. Methods and formulations for reducing circulating antibodies
US6458953B1 (en) 1998-12-09 2002-10-01 La Jolla Pharmaceutical Company Valency platform molecules comprising carbamate linkages
CN1762990A (zh) 1999-06-08 2006-04-26 拉卓拉药物公司 包含氨基氧基的化合价平台分子
MXPA02005236A (es) 1999-11-28 2004-03-19 Jolla Pharma Metodos de tratamiento de lupus con base en la afinidad de anticuerpos y metodos de separacion por exclusion y composiciones para el uso de los mismos.
AU2593901A (en) 1999-12-23 2001-07-03 Elusys Therapeutics, Inc. Therapeutic use of particles displaying pathogen-specific binding moieties
EP1284752A4 (en) 2000-04-26 2004-08-18 Elusys Therapeutics Inc BISPECIFIC MOLECULES AND USES THEREOF
WO2001093914A2 (en) 2000-06-08 2001-12-13 La Jolla Pharmaceutical Company Multivalent platform molecules comprising high molecular weight polyethylene oxide
US7405276B2 (en) 2000-11-01 2008-07-29 Elusys Therapeutics, Inc. Method of producing bispecific molecules by protein trans-splicing
JP2004529945A (ja) 2001-05-17 2004-09-30 ラ ホヤ ファーマシューティカル カンパニー Ｃｄ２１を阻害する薬剤を使用して抗体媒介性病理を処置する方法
US20030114405A1 (en) 2001-08-13 2003-06-19 Linnik Matthew D. Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
WO2004060320A2 (en) 2002-12-27 2004-07-22 La Jolla Pharmaceutical Company Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20040258683A1 (en) 2003-03-30 2004-12-23 Linnik Matthew D. Methods of treating and monitoring systemic lupus erythematosus in individuals

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
REFRENCES CITED IN WO 2001/041813 *

Also Published As

Publication number Publication date
AU3970201A (en) 2001-06-18
NO20022441L (no) 2002-07-09
NO20022441D0 (no) 2002-05-23
WO2001041813A2 (en) 2001-06-14
CN1399562A (zh) 2003-02-26
CA2391944A1 (en) 2001-06-14
EP1233791A2 (en) 2002-08-28
MXPA02005236A (es) 2004-03-19
CN101422614A (zh) 2009-05-06
KR20020059808A (ko) 2002-07-13
US7081242B1 (en) 2006-07-25
AU783282B2 (en) 2005-10-06
WO2001041813A3 (en) 2002-01-03
HK1045944A1 (zh) 2002-12-20
JP2003516526A (ja) 2003-05-13
US20060142229A1 (en) 2006-06-29

Similar Documents

Publication Publication Date Title
AU2021201773B2 (en) Methods and compositions for treating autoimmune and inflammatory conditions
US20100152281A1 (en) Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
US10570208B2 (en) Antagonistic anti-OX40L antibodies and methods of their use
US20040258683A1 (en) Methods of treating and monitoring systemic lupus erythematosus in individuals
US20060246123A1 (en) Oligonucleotide mimetics
AU783282C (en) Methods of treating lupus based on antibody affinity and screening methods and compositions for use thereof
JP2002531531A (ja) 循環している抗体を減少させるための方法および処方物
US20070218072A1 (en) Methods of improving health-related quality of life in individuals with systemic lupus erythematosus
US20060229270A1 (en) Methods of treating proteinuria by reducing double-stranded DNA antibodies
CA2355348A1 (en) Methods of treating systemic lupus erythematosus in individuals having significantly impaired renal function
CA2957314C (en) Antagonistic anti-ox40l antibodies and methods of their use
KR20070044813A (ko) 이뮤노글로불린 ｅ에 대한 핵산 리간드 및 아토피성 질환치료제로서의 이의 용도
Rasmussen et al. Specificity of antibodies raised against a specific phosphoromonothioate oligonucleotide sequence